The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $1.23 in the last session, up 5.13% from day before closing price of $1.17. In other words, the price has increased by $5.13 from its previous closing price. On the day, 5.01 million shares were traded. ESPR stock price reached its highest trading level at $1.26 during the session, while it also had its lowest trading level at $1.175.
Ratios:
We take a closer look at ESPR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.81 and its Current Ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Looker Benjamin sold 6,422 shares for $1.15 per share. The transaction valued at 7,398 led to the insider holds 401,241 shares of the business.
Koenig Sheldon L. sold 30,474 shares of ESPR for $33,796 on Jun 17 ’25. The President and CEO now owns 1,541,488 shares after completing the transaction at $1.11 per share. On Jun 17 ’25, another insider, Halladay Benjamin, who serves as the Chief Financial Officer of the company, sold 7,229 shares for $1.15 each. As a result, the insider received 8,328 and left with 474,473 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 243784784 and an Enterprise Value of 674477568. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.94. Its current Enterprise Value per Revenue stands at 2.598 whereas that against EBITDA is -16.898.
Stock Price History:
The Beta on a monthly basis for ESPR is 0.78, which has changed by -0.5060241 over the last 52 weeks, in comparison to a change of 0.12153554 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 23.35%, while the 200-Day Moving Average is calculated to be -28.08%.
Shares Statistics:
According to the various share statistics, ESPR traded on average about 5.04M shares per day over the past 3-months and 3247100 shares per day over the past 10 days. A total of 196.66M shares are outstanding, with a floating share count of 194.62M. Insiders hold about 1.80% of the company’s shares, while institutions hold 57.37% stake in the company. Shares short for ESPR as of 1749772800 were 24113664 with a Short Ratio of 4.78, compared to 1747267200 on 27945316. Therefore, it implies a Short% of Shares Outstanding of 24113664 and a Short% of Float of 12.2200005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Esperion Therapeutics Inc (ESPR) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.06, with high estimates of $0.2 and low estimates of -$0.16.
Analysts are recommending an EPS of between $0.09 and -$0.57 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.2, with 5.0 analysts recommending between $0.03 and -$0.44.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $62.87M. It ranges from a high estimate of $72.2M to a low estimate of $53.4M. As of the current estimate, Esperion Therapeutics Inc’s year-ago sales were $73.83MFor the next quarter, 8 analysts are estimating revenue of $93.39M. There is a high estimate of $195M for the next quarter, whereas the lowest estimate is $60.6M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $418M, while the lowest revenue estimate was $246.7M, resulting in an average revenue estimate of $347.26M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $328.28M in the next fiscal year. The high estimate is $413.2M and the low estimate is $257.95M.
